AIG-backed cancer and genetic disease developer BridgeBio Pharma has filed for a $225m initial public offering on the Nasdaq Global Market.
US-based genetic disease drug developer BridgeBio Pharma filed on Friday to raise up to $225m in an initial public offering that will enable insurance and financial services group AIG to exit.
BridgeBio is developing treatments for Mendelian diseases, which are caused by defects in a single specific gene, in addition to forms of cancer that are driven by genetic issues, and it has a 15-strong pipeline of drug candidates.
The IPO proceeds will fund product development, preclinical studies and…
